Fleury (FLRY3.SA) Saham Harga

Fleury Harga

B3·DITUTUP
20,79
​
Pasar ditutup

Selama 19 tahun terakhir pendapatan Fleury tumbuh 16,1% per tahun, mencapai 8,29 miliar BRL. Laba per saham tumbuh 16,8% per tahun selama 19 tahun terakhir. Bagi Fleury, margin bersih sebesar 7,4% turun dibanding 9,0% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 8,06%. Rasio pembayaran sekitar 149% dari laba. Dividen tumbuh 20,5% per tahun selama 15 tahun terakhir. Target harga konsensus 12 bulan untuk Fleury adalah 18,36 BRL, sekitar di bawah harga saat ini 11,7%. Dari 19 analis, 11 merekomendasikan beli — konsensus keseluruhan Beli.

Harga saham Fleury

Akses data ini lewat Eulerpool API

100.000 permintaan/bulan gratis · tanpa kartu

Model bisnis dan analisis saham Fleury

Sejarah Fleury SA dimulai pada tahun 1926 ketika keluarga Fleury membuka sebuah toko daging kecil di Lyon, Prancis. Keluarga ini dengan cepat mendapatkan reputasi atas kualitas tinggi dari daging dan sosis mereka serta mulai memasok restoran dan hotel. Selama beberapa dekade berikutnya, Fleury SA berkembang menjadi perusahaan terkemuka dalam industri makanan. Manajemen menyadari pentingnya inovasi dan diversifikasi sejak dini, sehingga perusahaan menjadi penyedia utama produk beku dan segar, termasuk daging, ikan, dan sayuran. Saat ini, Fleury SA adalah perusahaan yang beroperasi secara internasional dengan basis di Lyon dan memiliki cabang di beberapa negara. Bisnis inti perusahaan mencakup produksi dan pemasaran makanan dalam empat area berbeda: 1) Produk segar: Fleury SA dikenal karena daging dan sosis berkualitas tinggi, termasuk sapi, babi, unggas, dan daging buruan. Perusahaan juga menawarkan berbagai produk ikan, termasuk salmon, trout, dan tuna. 2) Produk beku: Fleury SA merupakan pemasok signifikan produk beku, termasuk daging, ikan, sayuran, dan makanan siap saji. Perusahaan sangat menekankan kualitas tinggi dan keberlanjutan produknya. 3) Bahan makanan: Fleury SA juga memproduksi berbagai bahan makanan yang banyak digunakan dalam industri pangan, termasuk rempah-rempah, herbal, dan perasa. 4) Merek dagang pribadi: Divisi penting lainnya dari Fleury SA adalah produksi merek dagang pribadi. Perusahaan bekerja sama dengan pengecer untuk memproduksi produk mereka di bawah merek masing-masing. Produk Fleury SA dijual melalui berbagai saluran distribusi, termasuk supermarket, restoran, dan hotel. Perusahaan juga mengandalkan kehadiran online yang kuat dan menawarkan berbagai produk melalui toko online mereka. Selama bertahun-tahun, perusahaan telah menerima numerous penghargaan atas produk dan inovasinya. Fleury SA bangga atas upayanya mempromosikan praktik bisnis yang berkelanjutan dan etis, serta berkomitmen terhadap perlindungan lingkungan dan kesejahteraan hewan dalam industri makanan. Secara keseluruhan, Fleury SA adalah perusahaan yang sukses dan inovatif, tetap setia pada akar dan nilai-nilainya. Melalui fokus pada kualitas, keberlanjutan, dan diversifikasi, perusahaan telah mengamankan posisi yang kokoh dalam industri makanan.

Pertanyaan yang sering diajukan tentang saham Fleury

The business model of Fleury SA, a leading medical diagnostics company in Brazil, revolves around providing high-quality healthcare services through its network of diagnostic imaging, clinical analysis, and other medical services. Fleury SA aims to ensure accurate diagnoses, offer timely access to medical procedures, and deliver exceptional customer experience. By investing in advanced technology, top-notch professionals, and continuous innovation, Fleury SA effectively meets the healthcare needs of patients across the country. With its strong reputation and diverse range of diagnostic services, Fleury SA strives to maintain its position as a market leader in Brazil's healthcare industry.

Fleury SA is primarily active in the healthcare industry.

The main competitors of Fleury SA in the market include Grupo Fleury, DASA, and Hermes Pardini.

Fleury SA is a leading healthcare company based in Brazil. With a rich history dating back to 1926, Fleury has continually evolved and expanded its operations to become one of the most reputable diagnostic medicine providers in the country. Over the years, the company has developed a strong reputation for its advanced diagnostic techniques and high-quality services, encompassing radiology, pathology, and clinical analysis. With a strong focus on technological innovation, Fleury has consistently invested in cutting-edge equipment and research, enabling them to deliver accurate and reliable results to patients. Today, Fleury SA stands as a trusted name in the healthcare industry, providing comprehensive diagnostic solutions to improve patient outcomes.

Fleury SA, a renowned company, has achieved remarkable milestones throughout its history. Having established a strong presence in the healthcare sector, Fleury SA continuously strives for excellence. Some significant achievements include expanding its network and becoming one of the largest healthcare providers in Brazil. Additionally, Fleury SA has consistently prioritized innovation, implementing advanced technology and processes to deliver high-quality diagnostics and medical solutions. The company's commitment to patient-centric care and a strong focus on research & development have further solidified its position as a trusted leader in the industry. Fleury SA's relentless pursuit of growth and unwavering dedication to improving healthcare services have contributed to its notable achievements.

Fleury SA is primarily present in Brazil, where it operates a wide network of diagnostic medicine and healthcare facilities. With its headquarters in São Paulo, the company is a leader in medical laboratory services, operating in several states across the country. Fleury SA's commitment to providing high-quality diagnostic services has allowed it to expand its presence to other regions of Brazil, catering to a diverse range of patients and medical professionals.

Fleury SA represents a strong set of values and corporate philosophy. With a focus on excellence and innovation, the company strives to deliver the highest quality healthcare services to patients. Fleury SA is committed to providing accurate diagnoses, personalized care, and cutting-edge medical technology. Through continuous improvement, the company aims to surpass industry standards and meet the evolving needs of its customers. With a reputation for professionalism and integrity, Fleury SA upholds a patient-centric approach, putting the well-being and satisfaction of individuals at the forefront. By encompassing these values, Fleury SA remains a trusted leader in the healthcare industry.

Analis saat ini menetapkan target harga rata-rata 17,77 BRL untuk saham Fleury (median: 18,36 BRL), yaitu -14,4 % terhadap harga terbaru. Konsensus didasarkan pada 19 peringkat analis.

18 analis saat ini menilai saham Fleury: 11 merekomendasikan beli, 5 tahan, dan 2 jual. Untuk 2026, analis memperkirakan Fleury menghasilkan pendapatan 9,29 miliar BRL dan laba per saham 1,48 BRL.

Dengan kurs saat ini, saham Fleury diperdagangkan pada 3,27 EUR (20,79 BRL).

Saham Fleury (FLRY3.SA) tercatat di 2 bursa, termasuk: B3 (São Paulo) (FLRY3.SA).

Fleury SA is a company specializing in medical diagnostics and health services. Founded in 1926, the company is headquartered in Sao Paulo, Brazil. With over 9,000 employees and a revenue of more than 2.2 billion Brazilian Reals, Fleury SA is one of the largest medical service companies in South America. The business model of Fleury SA is based on three core areas: diagnostics, health services, and research and development. In diagnostics, the company enables disease identification and offers comprehensive diagnostic solutions. The portfolio of diagnostic services is very broad and includes imaging and radiological diagnostics, laboratory and pathology services, genetic testing, and screening for pregnancy-related diseases. In the field of health services, Fleury SA offers a wide range of services for individuals and companies looking to improve prevention, wellness, and quality of life. The services range from health counseling and health programs to outpatient surgery and rehabilitation facilities. In research and development, the company is interested in driving innovation in the fields of medical diagnostics and health services. Fleury SA invests heavily in the development of new technologies and solutions to improve the accuracy and efficiency of its diagnostic services, as well as in collaboration with academic institutions and other companies. The company is known for adhering to very high quality standards in all aspects of its services. Fleury SA is ISO 9001 certified and is committed to continuously working towards customer satisfaction and process optimization. The company is proud to offer state-of-the-art technology and top-notch medical professionals to provide customers with the best possible service. In addition to its business areas, Fleury SA also offers a variety of products, such as diagnostic instruments and consumables for medical professionals, medical software, and health products for the general public. The products are designed to meet the needs of medical professionals and private consumers and meet the highest quality standards. Overall, Fleury SA has an impressive track record in the field of medical diagnostics and health services. The company has established itself as a trusted provider of high-quality and innovative solutions over the past decades and is committed to continuing to lead the industry with excellence and groundbreaking innovations.

Pendapatan diperkirakan dari Fleury adalah 9,29 miliar BRL. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari Fleury adalah 803,99 Juta. BRL. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Fleury saat ini adalah 14,09. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Fleury.

Rasio harga-terhadap-penjualan (PSR) Fleury saat ini adalah 1,22. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Fleury.

Skor Kualitas AlleAktien untuk Fleury adalah 7/10.

ISIN dari Fleury adalah BRFLRYACNOR5. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

Ticker dari Fleury adalah FLRY3.SA. Simbol ticker digunakan untuk memperdagangkan saham Fleury di bursa saham.

Nilai WajarTerminal
17,26 BRL
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Penyedia Layanan Kesehatan & Jasa
Jumlah Saham
Karyawan
Pendapatan per Karyawan
496.477,96 BRL
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Situs Web fleury.com.br
Negara
Brasil
Mata Uang
BRL
Penawaran Umum Perdana
16 Des 2009
ISIN
BRFLRYACNOR5
CUSIP
P418BW104
SEDOL
B4X4D29
Kapitalisasi Pasar
Kisaran 52 Minggu
Rasio PEG
1,78
P/E 2026
14,09
P/E 2027
12,26
P/E 2028
10,67
P/E 2029
10,14
P/E 2030
8,59
P/S
P/S
1,22
EV/EBIT
13,54
Rasio P/B
2,27
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5,97 %
Dividen
Hasil dividen
8,06 %
Hasil Dividen Estimasi
3,86 %
Rasio Pembayaran
149,00 %
Pertumbuhan dividen Ø5T
—
Pembayaran dividen per tahun
3
Dividen dibayarkan sejak
16 tahun
Dividen tidak dipotong sejak
2 tahun
Dividen meningkat sejak
2 tahun
Pajak penahan dividen
10,00 %
Terakhir diperbarui 19 Nov 2026, 11.03

Kelompok Peer Fleury

Fleury Ticker

B3 · FLRY3.SAB3 · FLRY3.SA

Fleury FIGI

FLRY3:BZ · BBG000PRQZM2FLRY3:BS · BBG000PRR0C9FLRY3:BN · BBG000PRR1F4FLRYF:PQ · BBG004V9MJ74FLRYF:UV · BBG004V9MJ92

Semua metrik fundamental dan analisis mendalam Fleury

Analisis saham kami untuk saham Fleury mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Fleury. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.